News-Medical.Net on MSN
BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services
BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that ...
Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...
StockStory.org on MSN
MRNA Q3 Deep Dive: Cost Controls and Pipeline Progress Amid Declining COVID Vaccine Demand
Biotechnology company Moderna (NASDAQ:MRNA) reported in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On ...
Elegen has launched ENFINIA™ IVT Ready DNA, a cell-free gene synthesis platform that provides full-length linear DNA templates encoded poly(A) tails.
Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.
Translation factors eIF1A and eIF5B are key repressors of an abnormal protein translation process linked to neurodegenerative ...
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer ...
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback